Newsroom

Novartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.

An essay by Vas Narasimhan, CEO of Novartis about the historical context and coming innovations in medicine with an introduction by Goran Mijuk.

Hear from Director of Patient Services at AAMDSIF on how she supports patients with PNH, a blood disorder that significantly impacts quality of life.

Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?

Alexandra Cossio Duque, a clinical and community research coordinator from Colombia, has travelled the world to study how to overcome social and geographic barriers to healthcare access. Today, she is working in her home country to strengthen the capacity of health systems to treat leishmaniasis, a neglected tropical disease that is endemic to rural areas of Colombia.

Cardiovascular disease is the leading cause of death in the US, claiming one in four lives. Social factors such as living conditions, education and diet play a key role in determining a person’s heart health, which means cardiovascular disease typically hits vulnerable communities the hardest. Our three-year Closing the Gap initiative with the Jefferson Collaborative for Health Equity (established by Jefferson Health and Thomas Jefferson University) focuses on addressing the upstream social determinants of heart health in five vulnerable neighborhoods in Philadelphia with high rates of stroke and adverse outcomes related to heart disease.

After being diagnosed with advanced prostate cancer, Van Lacour received a Novartis radioligand therapy as part of a managed access program in 2021. Today, he is living a fulfilling life in his hometown of Natchez, Louisiana, US.

As part of the Beacon of Hope initiative, the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts, US, offers 10-week paid summer fellowships for students at Historically Black Medical Schools to gain experience in drug discovery, data analytics and clinical research practices - with the goal of training up to 250 scientific leaders over 10 years.

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.